Jacques F Meis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11208321/publications.pdf

Version: 2024-02-01

218 papers	19,357 citations	14655 66 h-index	14208 128 g-index
220 all docs	220 docs citations	220 times ranked	11362 citing authors

#	Article	IF	Citations
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
2	Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clinical Infectious Diseases, 2017, 64, 134-140.	5.8	1,099
3	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
4	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	9.1	586
5	First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrobial Resistance and Infection Control, 2016, 5, 35.	4.1	535
6	Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathogens, 2017, 13, e1006290.	4.7	501
7	Azole Resistance inAspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. Clinical Infectious Diseases, 2016, 62, 362-368.	5.8	468
8	Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. Journal of Clinical Microbiology, 2015, 53, 1823-1830.	3.9	409
9	A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009â€“17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 891-899.	3.0	380
10	First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. Journal of Infection, 2016, 73, 369-374.	3.3	340
11	New Clonal Strain ofCandida auris, Delhi, India. Emerging Infectious Diseases, 2013, 19, 1670-1673.	4.3	320
12	Fusarium: Molecular Diversity and Intrinsic Drug Resistance. PLoS Pathogens, 2016, 12, e1005464.	4.7	314
13	Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health. PLoS Pathogens, 2013, 9, e1003633.	4.7	300
14	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
15	Potential Fifth Clade ofCandida auris,Iran, 2018. Emerging Infectious Diseases, 2019, 25, 1780-1781.	4.3	257
16	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	7.3	255
17	Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species. Antimicrobial Agents and Chemotherapy, 2012, 56, 2635-2642.	3.2	244
18	Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150460.	4.0	243

#	Article	IF	Citations
19	High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses, 2018, 61, 477-484.	4.0	237
20	An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses, 2018, 61, 498-505.	4.0	236
21	Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment. Journal of Infectious Diseases, 2017, 216, S436-S444.	4.0	199
22	Clonal Expansion and Emergence of Environmental Multiple-Triazole-Resistant Aspergillus fumigatus Strains Carrying the TR34/L98H Mutations in the cyp51A Gene in India. PLoS ONE, 2012, 7, e52871.	2.5	180
23	COVID-19â€“Associated Pulmonary Aspergillosis, Marchâ€“August 2020. Emerging Infectious Diseases, 2021, 27, 1077-1086.	4.3	175
24	Allergic bronchopulmonary mycosis due to fungi other thanAspergillus: a global overview. Critical Reviews in Microbiology, 2014, 40, 30-48.	6.1	174
25	Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. Journal of Antimicrobial Chemotherapy, 2012, 67, 362-366.	3.0	173
26	Genomic Context of Azole Resistance Mutations in Aspergillus fumigatus Determined Using Whole-Genome Sequencing. MBio, 2015, 6, e00536.	4.1	171
27	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The, 2021, 21, e246-e257.	9.1	167
28	High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 869-874.	3.2	164
29	Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Diversity, 2014, 67, 1-10.	12.3	152
30	Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management. Journal of Fungi (Basel, Switzerland), 2019, 5, 55.	3.5	149
31	Epidemiology and molecular mechanisms of antifungal resistance inÂCandida and Aspergillus. Mycoses, 2016, 59, 198-219.	4.0	142
32	ECMM/ISHAM recommendations for clinical management of COVIDâ€19 associated mucormycosis in lowâ€• and middleâ€•income countries. Mycoses, 2021, 64, 1028-1037.	4.0	137
33	Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales. Journal of Clinical Microbiology, 2012, 50, 66-75.	3.9	134
34	Autochthonous and DormantCryptococcus gattiiInfections in Europe. Emerging Infectious Diseases, 2012, 18, 1618-1624.	4.3	132
35	Molecular Epidemiology of Aspergillus fumigatus Isolates Harboring the TR ₃₄ /L98H Azole Resistance Mechanism. Journal of Clinical Microbiology, 2012, 50, 2674-2680.	3.9	127
36	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the Cryptococcus Genus. MSphere, 2017, 2, .	2.9	124

#	Article	IF	Citations
37	In-host adaptation and acquired triazole resistance in Aspergillus fumigatus : a dilemma for clinical management. Lancet Infectious Diseases, The, 2016, 16, e251-e260.	9.1	123
38	Ancient Dispersal of the Human Fungal Pathogen Cryptococcus gattii from the Amazon Rainforest. PLoS ONE, 2013, 8, e71148.	2.5	122
39	Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. Journal of Antimicrobial Chemotherapy, 2014, 69, 2979-2983.	3.0	122
40	In Vitro Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental Cryptococcus gattii Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 5139-5145.	3.2	121
41	Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiology, 2014, 9, 697-711.	2.0	118
42	Triazole resistance surveillance in Aspergillus fumigatus. Medical Mycology, 2018, 56, S83-S92.	0.7	114
43	Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. Journal of Antimicrobial Chemotherapy, 2014, 69, 555-557.	3.0	113
44	Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae. Antimicrobial Agents and Chemotherapy, 2015, 59, 6581-6587.	3.2	106
45	A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence. MBio, 2017, 8, .	4.1	104
46	Environmental study of azoleâ€resistant <scp>A</scp>spergillus fumigatus with TR₃₄/L98H mutations in the cyp51A gene in <scp>I</scp>ran. Mycoses, 2013, 56, 659-663.	4.0	98
47	Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses, 2018, 61, 377-382.	4.0	98
48	Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia. Scientific Reports, 2017, 7, 45631.	3.3	96
49	A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. Fungal Genetics and Biology, 2019, 133, 103266.	2.1	93
50	Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Frontiers in Microbiology, 2015, 06, 428.	3.5	89
51	Multiâ€triazoleâ€resistant Aspergillus fumigatus infections in Australia. Mycoses, 2015, 58, 350-355.	4.0	89
52	Global molecular epidemiology and genetic diversity of Fusarium , a significant emerging group of human opportunists from 1958 to 2015. Emerging Microbes and Infections, 2016, 5, 1-11.	6.5	89
53	Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report. Journal of Fungi (Basel, Switzerland), 2020, 6, 79.	3.5	88
54	Identification and typing of the emerging pathogen Candida auris by matrixâ€assisted laser desorption ionisation time of flight mass spectrometry. Mycoses, 2016, 59, 535-538.	4.0	86

#	Article	IF	Citations
55	Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infectious Diseases, 2018, 18, 24.	2.9	86
56	The worldâ€™s ten most feared fungi. Fungal Diversity, 2018, 93, 161-194.	12.3	85
57	Current antifungal treatment of fusariosis. International Journal of Antimicrobial Agents, 2018, 51, 326-332.	2.5	83
58	Geographically Structured Populations of Cryptococcus neoformans Variety grubii in Asia Correlate with HIV Status and Show a Clonal Population Structure. PLoS ONE, 2013, 8, e72222.	2.5	83
59	Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. Journal of Antimicrobial Chemotherapy, 2015, 70, 1068-71.	3.0	81
60	Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired?. Journal of Global Antimicrobial Resistance, 2015, 3, 69-74.	2.2	81
61	Passive Surveillance for Azole-ResistantAspergillus fumigatus, United States, 2011â€“2013. Emerging Infectious Diseases, 2014, 20, 1498-1503.	4.3	76
62	Recognizing filamentous basidiomycetes as agents of human disease: A review. Medical Mycology, 2014, 52, 782-797.	0.7	76
63	Taxonomy of the Trichophyton mentagrophytes/T. interdigitale Species Complex Harboring the Highly Virulent, Multiresistant Genotype T. indotineae. Mycopathologia, 2021, 186, 315-326.	3.1	76
64	In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	75
65	Candida auris otomycosis in Iran and review of recent literature. Mycoses, 2019, 62, 101-105.	4.0	75
66	Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nature Microbiology, 2020, 5, 1516-1531.	13.3	75
67	Global Population Genetic Analysis of Aspergillus fumigatus. MSphere, 2017, 2, .	2.9	71
68	Nonrandom Distribution of Azole Resistance across the Global Population of Aspergillus fumigatus. MBio, 2019, 10, .	4.1	71
69	Environmental prevalence ofCryptococcus neoformansandCryptococcus gattiiin India: An update. Critical Reviews in Microbiology, 2012, 38, 1-16.	6.1	70
70	Candida auris: a global fungal public health threat. Lancet Infectious Diseases, The, 2018, 18, 1298-1299.	9.1	69
71	The first cases of Candida auris candidaemia in Oman. Mycoses, 2017, 60, 569-575.	4.0	66
72	In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba. Antimicrobial Agents and Chemotherapy, 2008, 52, 1580-1582.	3.2	65

#	Article	IF	Citations
73	Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogenAspergillus fumigatus. Molecular Ecology, 2012, 21, 57-70.	3.9	65
74	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. Journal of Clinical Microbiology, 2015, 53, 1056-1062.	3.9	65
75	Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. Journal of Antimicrobial Chemotherapy, 2010, 65, 901-905.	3.0	64
76	Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait. Environmental Research, 2014, 133, 20-26.	7.5	64
77	In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses, 2015, 58, 303-307.	4.0	64
78	Intercountry Transfer of Triazole-Resistant Aspergillus fumigatus on Plant Bulbs. Clinical Infectious Diseases, 2017, 65, 147-149.	5.8	63
79	Draft Genome Sequence of a Fluconazole-Resistant Candida auris Strain from a Candidemia Patient in India. Genome Announcements, 2015, 3, .	0.8	62
80	Candida auris. Current Opinion in Infectious Diseases, 2018, 31, 334-340.	3.1	62
81	Temperate Climate Niche forCryptococcus gattiiin Northern Europe. Emerging Infectious Diseases, 2012, 18, 172-174.	4.3	62
82	First Description of Azole-Resistant Aspergillus fumigatus Due to TR ₄₆ /Y121F/T289A Mutation in France. Antimicrobial Agents and Chemotherapy, 2015, 59, 4331-4335.	3.2	61
83	Emergence of clonal fluconazole-resistant Candida parapsilosis clinical isolates in a multicentre laboratory-based surveillance study in India. Journal of Antimicrobial Chemotherapy, 2019, 74, 1260-1268.	3.0	61
84	No to Neocosmospora : Phylogenomic and Practical Reasons for Continued Inclusion of the Fusarium solani Species Complex in the Genus Fusarium. MSphere, 2020, 5, .	2.9	61
85	Clinical Significance and Molecular Characterization of Nonsporulating Molds Isolated from the Respiratory Tracts of Bronchopulmonary Mycosis Patients with Special Reference to Basidiomycetes. Journal of Clinical Microbiology, 2013, 51, 3331-3337.	3.9	60
86	Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 2855-2866.	3.2	60
87	EQUAL Candida Score: An <scp>ECMM</scp> score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses, 2018, 61, 326-330.	4.0	60
88	Development of Candida auris Short Tandem Repeat Typing and Its Application to a Global Collection of Isolates. MBio, 2020, 11, .	4.1	56
89	Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. Journal of Antimicrobial Chemotherapy, 2015, 70, 412-415.	3.0	55
90	Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerging Microbes and Infections, 2016, 5, 1-12.	6.5	55

#	Article	IF	Citations
91	Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients â€“ A Dutch, multicentre study. Journal of Cystic Fibrosis, 2019, 18, 221-226.	0.7	55
92	Clade-specific chromosomal rearrangements and loss of subtelomeric adhesins in Candida auris. Genetics, 2021, 218, .	2.9	54
93	Extensive Genetic Diversity within the Dutch Clinical Cryptococcus neoformans Population. Journal of Clinical Microbiology, 2012, 50, 1918-1926.	3.9	53
94	Molecular Epidemiology and In-Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Isolates in Delhi, India: Evidence of Genetic Diversity by Amplified Fragment Length Polymorphism and Microsatellite Typing. PLoS ONE, 2015, 10, e0118997.	2.5	53
95	In vitrocombinations of natamycin with voriconazole, itraconazole and micafungin against clinicalFusariumstrains causing keratitis: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 953-955.	3.0	53
96	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	4.0	52
97	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999â€“2015. Clinical Infectious Diseases, 2017, 65, 216-225.	5.8	50
98	Azole resistance surveillance inAspergillus fumigatus: beneficial or biased?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2079-2082.	3.0	49
99	Antifungal Susceptibility Testing of Fusarium: A Practical Approach. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	3.5	49
100	Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil. Frontiers in Microbiology, 2019, 10, 737.	3.5	49
101	Killing of Candida auris by <scp>UV</scp>â€: Importance of exposure time and distance. Mycoses, 2019, 62, 408-412.	4.0	49
102	Antifungal Susceptibility and Mutations in the Squalene Epoxidase Gene in Dermatophytes of the Trichophyton mentagrophytes Species Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0005621.	3.2	49
103	Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. Mycoses, 2014, 57, 97-107.	4.0	48
104	Home Environment as a Source of Life-Threatening Azole-ResistantAspergillus fumigatusin Immunocompromised Patients: Table 1.. Clinical Infectious Diseases, 2017, 64, 76-78.	5.8	48
105	Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS. Frontiers in Cellular and Infection Microbiology, 2019, 9, 20.	3.9	48
106	COVIDâ€19â€“associated pulmonary aspergillosis: a prospective singleâ€center dual case series. Mycoses, 2021, 64, 457-464.	4.0	48
107	Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital. Frontiers in Cellular and Infection Microbiology, 2020, 10, 232.	3.9	48
108	Emergence of azole resistant Aspergillus fumigatus and One Health: time to implement environmental stewardship. Environmental Microbiology, 2018, 20, 1299-1301.	3.8	47

#	Article	IF	Citations
109	In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses, 2011, 54, e583-9.	4.0	46
110	Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis?. PLoS Pathogens, 2016, 12, e1005491.	4.7	46
111	Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses, 2016, 59, 576-584.	4.0	46
112	Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013â€“2018. Emerging Infectious Diseases, 2020, 26, 1447-1455.	4.3	46
113	In Vitro Antifungal Activity of Isavuconazole against Madurella mycetomatis. Antimicrobial Agents and Chemotherapy, 2012, 56, 6054-6056.	3.2	45
114	Resistance of Asian Cryptococcus neoformans Serotype A Is Confined to Few Microsatellite Genotypes. PLoS ONE, 2012, 7, e32868.	2.5	42
115	Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. Antimicrobial Agents and Chemotherapy, 2015, 59, 7882-7887.	3.2	41
116	Candida nivariensis Isolated from an Indonesian Human Immunodeficiency Virus-Infected Patient Suffering from Oropharyngeal Candidiasis. Journal of Clinical Microbiology, 2008, 46, 388-391.	3.9	40
117	DNA barcoding, MALDI-TOF, and AFLP data support Fusarium ficicrescens as a distinct species within the Fusarium fujikuroi species complex. Fungal Biology, 2016, 120, 265-278.	2.5	40
118	Perspectives on misidentification of Trichophyton interdigitale/Trichophyton mentagrophytes using internal transcribed spacer region sequencing: Urgent need to update the sequence database. Mycoses, 2019, 62, 11-15.	4.0	40
119	Axillary Digital Thermometers uplifted a multidrugâ€susceptible Candidaauris outbreak among COVIDâ€19 patients in Brazil. Mycoses, 2021, 64, 1062-1072.	4.0	40
120	Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 6916-6919.	3.2	39
121	Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates. Journal of Fungi (Basel, Switzerland), 2018, 4, 103.	3.5	38
122	Clinical Significance of Filamentous Basidiomycetes Illustrated by Isolates of the Novel Opportunist Ceriporia lacerata from the Human Respiratory Tract. Journal of Clinical Microbiology, 2013, 51, 585-590.	3.9	37
123	Global prevalence and subgroup analyses of coronavirus disease (<scp>COVID</scp>â€19) associated Candida auris infections (<scp>CACa</scp>): A systematic review and metaâ€analysis. Mycoses, 2022, 65, 683-703.	4.0	37
124	Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses, 2016, 59, 101-107.	4.0	36
125	Molecular Characterization and In Vitro Antifungal Susceptibility Profile of Schizophyllum commune, an Emerging Basidiomycete in Bronchopulmonary Mycoses. Antimicrobial Agents and Chemotherapy, 2013, 57, 2845-2848.	3.2	35
126	Ongoing Challenges with Healthcare-Associated Candida auris Outbreaks in Oman. Journal of Fungi (Basel, Switzerland), 2019, 5, 101.	3.5	34

#	Article	IF	Citations
127	Fungicide-driven alterations in azole-resistantAspergillus fumigatusare related to vegetable crops in Colombia, South America. Mycologia, 2019, 111, 217-224.	1.9	34
128	Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates. Mycoses, 2014, 57, 380-387.	4.0	33
129	Molecular Epidemiology of Candida Auris Outbreak in a Major Secondary-Care Hospital in Kuwait. Journal of Fungi (Basel, Switzerland), 2020, 6, 307.	3.5	33
130	Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	32
131	Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. Journal of Infection, 2016, 72, 745-752.	3.3	31
132	Effects of the Natural Peptide Crotamine from a South American Rattlesnake on Candida auris, an Emergent Multidrug Antifungal Resistant Human Pathogen. Biomolecules, 2019, 9, 205.	4.0	31
133	Ecoepidemiology of Cryptococcus gattii in Developing Countries. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	3.5	30
134	High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India. Journal of Fungi (Basel, Switzerland), 2020, 6, 67.	3.5	30
135	A rare case of allergic bronchopulmonary mycosis caused byAlternaria alternata. Medical Mycology, 2012, 50, 890-896.	0.7	29
136	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Journal of Antimicrobial Chemotherapy, 2018, 73, 134-142.	3.0	29
137	In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex. Mycoses, 2018, 61, 134-142.	4.0	29
138	Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2018, 4, 129.	3.5	29
139	First azoleâ€resistant Aspergillus fumigatus isolates with the environmental TR₄₆/Y121F/T289A mutation in Iran. Mycoses, 2020, 63, 430-436.	4.0	29
140	Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing. Journal of Fungi (Basel, Switzerland), 2021, 7, 81.	3.5	29
141	Internal validation of <scp>GPS</scp>^{â„¢}<scp>MONODOSE</scp> CanAur dtecâ€<scp>qPCR</scp> kit following the <scp>UNE</scp>/<scp>EN ISO</scp>/<scp>IEC</scp> 17025:2005 for detection of the emerging yeast Candida auris. Mycoses, 2018, 61, 877-884.	4.0	28
142	Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 50.	3.5	28
143	Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	27
144	Fusarium species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses, 2017, 60, 204-212.	4.0	26

#	Article	IF	Citations
145	Outbreak of Fusarium oxysporum infections in children with cancer: an experience with 7 episodes of catheter-related fungemia. Antimicrobial Resistance and Infection Control, 2017, 6, 93.	4.1	26
146	Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiaryâ€care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins. Mycoses, 2022, 65, 331-343.	4.0	25
147	In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species. Mycopathologia, 2019, 184, 607-613.	3.1	24
148	Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline? . Infection and Drug Resistance, 2019, Volume 12, 3727-3737.	2.7	24
149	A Cluster of Candida auris Blood Stream Infections in a Tertiary Care Hospital in Oman from 2016 to 2019. Antibiotics, 2020, 9, 638.	3.7	24
150	Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts. Open Forum Infectious Diseases, 2014, 1, ofu029.	0.9	23
151	In vitroactivity of the novel antifungal olorofim against dermatophytes and opportunistic moulds includingPenicilliumandTalaromycesspecies. Journal of Antimicrobial Chemotherapy, 2021, 76, 1229-1233.	3.0	23
152	Meningitis caused by Filobasidium uniguttulatum: case report and overview of the literature. Mycoses, 2012, 55, 105-109.	4.0	22
153	Evaluation of DermaGenius^{Â®} resistance realâ€time polymerase chain reaction for rapid detection of terbinafineâ€resistant Trichophyton species. Mycoses, 2021, 64, 721-726.	4.0	22
154	Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
155	Evaluation of Microsatellite Typing, ITS Sequencing, AFLP Fingerprinting, MALDI-TOF MS, and Fourier-Transform Infrared Spectroscopy Analysis of Candida auris. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	4.1	21
156	Simple, Low-Cost Molecular Assays for TR34/L98H Mutations in the cyp51A Gene for Rapid Detection of Triazole-Resistant Aspergillus fumigatus Isolates. Journal of Clinical Microbiology, 2014, 52, 2223-2227.	3.9	20
157	Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study. Medical Mycology, 2018, 56, 406-415.	0.7	20
158	Antifungal activity of nitroxoline against Candida auris isolates. Clinical Microbiology and Infection, 2021, 27, 1697.e7-1697.e10.	6.0	20
159	South Asian (Clade I) Candida auris meningitis in a paediatric patient in Iran with a review of the literature. Mycoses, 2022, 65, 134-139.	4.0	20
160	Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, Fusarium spp., and Scedosporium spp.. Diagnostic Microbiology and Infectious Disease, 2012, 73, 330-337.	1.8	19
161	ECMM CandiRegâ€”A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
162	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18

#	Article	IF	Citations
163	Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
164	The First Two Cases of CandidaÂauris in The Netherlands. Journal of Fungi (Basel, Switzerland), 2019, 5, 91.	3.5	18
165	A Chronic Autochthonous Fifth Clade Case of Candida auris Otomycosis in Iran. Mycopathologia, 2022, 187, 121-127.	3.1	18
166	Collateral consequences of agricultural fungicides on pathogenic yeasts: A One Health perspective to tackle azole resistance. Mycoses, 2022, 65, 303-311.	4.0	18
167	cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
168	Cryptococcal meningitis due to Cryptococcus neoformans genotype <scp>AFLP</scp>1/<scp>VNI</scp> in Iran: a review of the literature. Mycoses, 2015, 58, 689-693.	4.0	16
169	Clonal Expansion of Environmental Triazole Resistant Aspergillus fumigatus in Iran. Journal of Fungi (Basel, Switzerland), 2020, 6, 199.	3.5	16
170	Fatal Cryptococcus gattii genotype AFLP5 infection in an immunocompetent Cuban patient. Medical Mycology Case Reports, 2013, 2, 48-51.	1.3	15
171	Cryptococcus and Cryptococcosis in Cuba. A minireview. Mycoses, 2014, 57, 707-717.	4.0	15
172	Fusarium metavorans sp. nov.: The frequent opportunist â€˜FSSC6â€™. Medical Mycology, 2018, 56, S144-S152.	0.7	15
173	Postâ€influenzal triazoleâ€resistant aspergillosis following allogeneic stem cell transplantation. Mycoses, 2018, 61, 570-575.	4.0	15
174	In vitro characterization, ADME analysis, and histological and toxicological evaluation of BM1, a macrocyclic amidinourea active against azole-resistant Candida strains. International Journal of Antimicrobial Agents, 2020, 55, 105865.	2.5	15
175	Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. Journal of Medical Microbiology, 2018, 67, 560-569.	1.8	15
176	Comparative genotyping and phenotyping of Aspergillus fumigatus isolates from humans, dogs and the environment. BMC Microbiology, 2018, 18, 118.	3.3	14
177	Airway persistence by the emerging multiâ€azoleâ€resistant Rasamsonia argillacea complex in cystic fibrosis. Mycoses, 2018, 61, 665-673.	4.0	13
178	Molecular characterization of Cryptococcus gattii genotype AFLP6/VGII isolated from woody debris of divi-divi (Caesalpinia coriaria), Bonaire, Dutch Caribbean. Revista Iberoamericana De Micologia, 2014, 31, 193-196.	0.9	12
179	Are the TR ₄₆ /Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?. Antimicrobial Agents and Chemotherapy, 2016, 60, 3259-3260.	3.2	12
180	In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe. Diagnostic Microbiology and Infectious Disease, 2016, 86, 289-292.	1.8	12

#	Article	IF	Citations
181	Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus. Journal of Antimicrobial Chemotherapy, 2019, 74, 2950-2958.	3.0	12
182	Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 154.	3.5	12
183	External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris. Journal of Fungi (Basel, Switzerland), 2019, 5, 94.	3.5	11
184	Emergence of Candida auris in intensive care units in Algeria. Mycoses, 2022, 65, 753-759.	4.0	10
185	Comparison of biotyping methods as alternative identification tools to molecular typing of pathogenic <scp>C</scp>ryptococcus species in subâ€Saharan Africa. Mycoses, 2016, 59, 151-156.	4.0	9
186	Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients. Microbial Pathogenesis, 2018, 115, 353-357.	2.9	9
187	Mycotic Keratitis Caused by Fusarium solani sensu stricto (FSSC5): A Case Series. Mycopathologia, 2018, 183, 835-840.	3.1	9
188	Activities of nine antifungal agents against Candida auris biofilms. Mycoses, 2021, 64, 381-384.	4.0	9
189	Discovery of a sexual cycle inTalaromyces amestolkiae. Mycologia, 2016, 108, 70-79.	1.9	8
190	In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions. Diagnostic Microbiology and Infectious Disease, 2018, 91, 266-268.	1.8	8
191	Use of cell surface protein typing for genotyping of azoleâ€resistant and â€susceptible Aspergillus fumigatus isolates in Iran. Mycoses, 2018, 61, 143-147.	4.0	8
192	Thermogenic Characterization and Antifungal Susceptibility of Candida auris by Microcalorimetry. Journal of Fungi (Basel, Switzerland), 2019, 5, 103.	3.5	8
193	European confederation of medical mycology expert consultâ€"An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
194	Diagnostic Allele-Specific PCR for the Identification of Candida auris Clades. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.5	8
195	Microcalorimetry Assay for Rapid Detection of Voriconazole Resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 5704-5706.	3.2	7
196	Bipolaris oryzae, a novel fungal opportunist causing keratitis. Diagnostic Microbiology and Infectious Disease, 2016, 85, 61-65.	1.8	7
197	Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
198	Differential In Vitro Cytokine Induction by the Species of Cryptococcus gattii Complex. Infection and Immunity, 2018, 86, .	2.2	7

#	Article	IF	Citations
199	A novel diagnosis scoring model to predict invasive pulmonary aspergillosis in the intensive care unit. Journal of King Abdulaziz University, Islamic Economics, 2019, 40, 140-146.	1.1	7
200	A simple and low cost tetra-primer ARMS-PCR method for detection triazole-resistant Aspergillus fumigatus. Molecular Biology Reports, 2019, 46, 4537-4543.	2.3	7
201	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. Journal of Fungi (Basel, Switzerland), 2020, 6, 274.	3.5	7
202	Outbreak of Dirkmeia churashimaensis Fungemia in a Neonatal Intensive Care Unit, India. Emerging Infectious Diseases, 2020, 26, 764-768.	4.3	7
203	Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates. Mycopathologia, 2020, 185, 357-365.	3.1	6
204	Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer. Frontiers in Cellular and Infection Microbiology, 2021, 11, 645049.	3.9	6
205	Two Candida auris Cases in Germany with No Recent Contact to Foreign Healthcareâ€"Epidemiological and Microbiological Investigations. Journal of Fungi (Basel, Switzerland), 2021, 7, 380.	3.5	6
206	Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris. Current Medical Mycology, 2019, 5, 26-30.	0.8	6
207	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
208	Candida aurisâ€"â€œTen Years Afterâ€• Journal of Fungi (Basel, Switzerland), 2020, 6, 2.	3.5	4
209	International Society for Human and Animal Mycology (ISHAM)â€"New Initiatives. Journal of Fungi (Basel, Switzerland), 2020, 6, 97.	3.5	4
210	Non-traumatic keratitis due to Colletotrichum truncatum. JMM Case Reports, 2016, 3, e005047.	1.3	4
211	Reply to â€œImplications of High Antifungal Susceptibility on Schizophyllum commune-Associated Allergy in Clinical Practiceâ€• Antimicrobial Agents and Chemotherapy, 2013, 57, 5784-5785.	3.2	3
212	Does Online Search Behavior Coincide with Candida auris Cases? An Exploratory Study. Journal of Fungi (Basel, Switzerland), 2019, 5, 44.	3.5	3
213	Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant Aspergillus flavus Isolates. Journal of Fungi (Basel, Switzerland), 2021, 7, 164.	3.5	3
214	Cryptococcus gattii genotype AFLP6/VGII meningoencephalitis in an immunocompetent Filipino male in Kuwait: activation of a dormant infection. JMM Case Reports, 2015, 2, .	1.3	3
215	Brazil is so far free from Candida auris. Are we missing something?. Brazilian Journal of Infectious Diseases, 2019, 23, 149-150.	0.6	2
216	Multi-locus sequence typing reveals genotypic similarity in Nigerian Cryptococcus neoformans AFLP1/VNI of environmental and clinical origin. Journal of Medical Microbiology, 2021, 70, .	1.8	2

#	Article	IF	Citations
217	Antifungal resistance in clinically significant fungi. Fungal Genetics and Biology, 2020, 139, 103369.	2.1	1
218	In vitro activity of eight antifungal drugs against Chaetomiaceae. Medical Mycology, 2021, 60, .	0.7	1